Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Mayo Clinic Proceedings|November 24, 1999
Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trialW G Bensen, J J Fiechtner, J I McMillen, et al.
European Journal of Pain (London, England)|March 17, 2021
Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?Francis Berenbaum, Richard Langford, Serge Perrot, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 15, 2022
A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer ImmunotherapiesStephen Palmer, Isabelle Borget, Tim Friede, et al.
Clinical Pharmacology and Therapeutics|January 9, 2023
Predicting Treatment Responses in Patients With Osteoarthritis: Results From Two Phase III Tanezumab Randomized Clinical TrialsLuana Colloca, Robert H Dworkin, John T Farrar, et al.
Arthritis Research & Therapy|March 30, 2022
Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled studyTuhina Neogi, David J Hunter, Melvin Churchill, et al.
Cancer Medicine|April 21, 2015
Intensive care admission of cancer patients: a comparative analysisMonique M E M Bos, Ilona W M Verburg, Ineke Dumaij, et al.
Pain|May 27, 2020
Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safetyJohn D Markman, Robert B Bolash, Timothy E McAlindon, et al.
JAMA|December 2, 1999
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trialL S Simon, A L Weaver, D Y Graham, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 4, 2021
Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized TrialMarc C Hochberg, John A Carrino, Thomas J Schnitzer, et al.
Osteoarthritis and Cartilage|August 31, 2023
Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumabJohn A Carrino, Timothy E McAlindon, Tom J Schnitzer, et al.
Pageof 15